Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)

Hodgkin lymphoma (HL) patients who have relapsed after autologous hematopoietic cell transplantation (HCT) and received nivolumab may achieve adequate disease control and be eligible for allogeneic (allo)-HCT. US Prescribing Information recommends monitoring for allo-HCT complications after nivolumab —eg, hyperacute graft-versus-host disease (GVHD), grade (G) 3–4 GVHD, steroid-requiring febrile syndrome (SRFS), and other immune-mediated reactions.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Carmelo Carlo-Stella, Graham P. Collins, Philippe Armand, Pier Luigi Zinzani, Jonathon B. Cohen, Ahmad Halwani, Michael Millenson, Mariano Provencio, Eva Domingo Domenech, Lisa Giulino-Roth, Luca Castagna, Kazunobu Kato, Mihaela Popa McKiver, Anne Sumbul, Source Type: research